Ticker
ABEO

Price
2.76
Stock movement down
-0.06 (-2.13%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
47.41M
Ent verdi
65.02M
Pris/omsetning
10.91
Pris/bok
3.08
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
961.54%
3 års avkastning
4.48%
5 års avkastning
-29.32%
10 års avkastning
-16.62%
Sist oppdatert: 2023-02-03

UTBYTTE

ABEO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning10.91
Pris til bok3.08
EV i forhold til salg14.96

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall17.18M
EPS (TTM)-13.28
FCF per aksje (TTM)-7.64

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)4.35M
Bruttofortjeneste (TTM)4.00M
Driftsinntekter (TTM)-84.63M
Netto inntekt (TTM)-85.25M
EPS (TTM)-13.28
EPS (1 år fremover)-1.79

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)91.95%
Driftsmargin (TTM)-1947.33%
Fortjenestemargin (TTM)-1961.64%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter5.73M
Netto fordringer1.05M
Samlede omløpsmidler25.50M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler38.76M
Leverandørgjeld1.75M
Kortsiktig/nåværende langsiktig gjeld8.29M
Sum kortsiktig gjeld12.60M
Sum gjeld23.35M
Aksjonærenes egenkapital15.41M
Netto varige driftsmidler15.41M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-46.16M
Kapitalutgifter (TTM)2.91M
Fri kontantstrøm (TTM)-49.07M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-553.12%
Avkastning på eiendeler-219.95%
Avkastning på investert kapital-495.00%
Kontantavkastning på investert kapital-284.93%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.77
Daglig høy2.90
Daglig lav2.73
Daglig volum158K
Tidenes høyeste47188.00
1 år analytikerestimat21.33
Beta1.25
EPS (TTM)-13.28
Utbytte per aksje-
Ex-div dato22 Jul 2022
Neste dato for resultatpresentasjon29 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABEOS&P500
Nåværende prisfall fra toppnotering-99.99%-13.68%
Høyeste prisfall-100.00%-56.47%
Dato for høyeste fall17 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-92.03%-11.49%
Gj.snittlig tid til ny topp404 days13 days
Maks tid til ny topp7568 days1805 days
SELSKAPSOPPLYSNINGER
ABEO (Abeona Therapeutics Inc) company logo
Markedsverdi
47.41M
Markedsverdi kategori
Small-cap
Beskrivelse
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Ansatte
90
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Joao Siffert
Land
USA
By
New York
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14. november 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8. november 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3. november 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3. november 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3. november 2022
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its inv...
19. oktober 2022
Topline VIITAL™ study results expected within the next monthNEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has ...
4. oktober 2022
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside...
22. september 2022
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel di...
13. september 2022
In this article, we discuss 10 best penny stocks to buy in September. If you want to see more stocks in this selection, check out 5 Best Penny Stocks to Buy in September. As the stock market runs red,...
8. september 2022
Neste side